Angela Mastronuzzi: 131 I-mIBG therapy in relapsed/refractory neuroblastoma
Angela Mastronuzzi, Head of the Neuro-Oncology Unit at Bambino Gesù Children’s Hospital, shared a post on LinkedIn about an article by her and colleagues published in Critical Reviews in Oncology/Hematology:
“Just published with Elsevier:
Neuroblastoma (NB) is the most common extracranial solid tumor in children, with variable outcomes ranging from spontaneous remission to high-risk cases often leading to relapse or refractory disease. Approximately 50% of patients with NB have high-risk features, often experiencing relapse or refractory disease despite intensive treatments and the prognosis remains poor.
Radioactive iodine-labeled meta-iodobenzylguanidine (¹³¹I-mIBG) therapy, leveraging NB cells’ radiosensitivity and expression of the norepinephrine transporter (NET), has shown promise in treating relapsed or refractory NB.
Our systematic review, based on MEDLINE, EMBASE, and Cochrane CENTRAL databases up to December 2023, evaluates the effectiveness and toxicity of ¹³¹I-mIBG therapy in relapsed/refractory NB.
It also discusses its potential role in conjunction with emerging therapies like CAR-T cells, haploidentical stem cell transplantation, and dinutuximab beta.
Highlights:
- Long-term event-free survival rates in relapsed/refractory (RR) neuroblastoma (NB) < 10%
- ¹³¹I-mIBG therapy seems promising for RR NB
- Toxicity of ¹³¹I-mIBG is manageable
- Role of ¹³¹I-mIBG associated with emerging therapies (such as CAR-T cells) may be investigated and considered in the future strategies for RR NB.”
“131 I-mIGB therapy in relapsed/refractory neuroblastoma: a weapon from the future past”
Authors: Francesco Fabozzi, Maria Felicia Villani, Angela Mastronuzzi, Maria Antonietta De Ioris, Maria Carmen Garganese et al.
Angela Mastronuzzi is the President of AIEOP. She is a pediatric hematologist-oncologist and the Head of the Neuro-Oncology Unit at Bambino Gesù Children’s Hospital (Italy).
She is also a professor at the UniCamillus International Medical University, and a Board Member of AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica). Her main fields of interest are CNS tumors and innovative therapies.
More posts featuring Angela Mastronuzzi.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023